ATE541935T1 - Wachstumshormon fusionprotein - Google Patents

Wachstumshormon fusionprotein

Info

Publication number
ATE541935T1
ATE541935T1 AT02806858T AT02806858T ATE541935T1 AT E541935 T1 ATE541935 T1 AT E541935T1 AT 02806858 T AT02806858 T AT 02806858T AT 02806858 T AT02806858 T AT 02806858T AT E541935 T1 ATE541935 T1 AT E541935T1
Authority
AT
Austria
Prior art keywords
growth hormone
fusion protein
hormone fusion
modified
binding domain
Prior art date
Application number
AT02806858T
Other languages
English (en)
Inventor
Richard Ross
Jon Sayers
Peter Artymiuk
Original Assignee
Asterion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterion Ltd filed Critical Asterion Ltd
Application granted granted Critical
Publication of ATE541935T1 publication Critical patent/ATE541935T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
AT02806858T 2001-12-14 2002-12-06 Wachstumshormon fusionprotein ATE541935T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0130052A GB2384001B (en) 2001-12-14 2001-12-14 Chimeric growth hormone-growth hormone receptor proteins
PCT/GB2002/005523 WO2003070765A2 (en) 2001-12-14 2002-12-06 Growth hormone fusion protein

Publications (1)

Publication Number Publication Date
ATE541935T1 true ATE541935T1 (de) 2012-02-15

Family

ID=9927705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02806858T ATE541935T1 (de) 2001-12-14 2002-12-06 Wachstumshormon fusionprotein

Country Status (19)

Country Link
US (2) US7524649B2 (de)
EP (2) EP1456385B1 (de)
JP (2) JP5248734B2 (de)
KR (3) KR20040083470A (de)
CN (2) CN100558899C (de)
AT (1) ATE541935T1 (de)
AU (1) AU2002366325B2 (de)
CA (1) CA2468439A1 (de)
ES (1) ES2378424T3 (de)
GB (2) GB2384001B (de)
HU (1) HUP0402496A3 (de)
IL (3) IL162433A0 (de)
MX (1) MXPA04005675A (de)
NZ (1) NZ533550A (de)
PL (1) PL210714B1 (de)
RU (2) RU2346047C2 (de)
SG (1) SG160205A1 (de)
WO (1) WO2003070765A2 (de)
ZA (2) ZA200404488B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1290170A2 (de) * 2000-06-16 2003-03-12 Asterion Limited Bindungsreagenzien: chimäre ligand/rezeptorproteine
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
EP1771467A2 (de) * 2004-07-26 2007-04-11 Asterion Limited Linker
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
GB0606946D0 (en) * 2006-04-06 2006-05-17 Asterion Ltd Polypeptide antagonist
GB0618082D0 (en) * 2006-09-14 2006-10-25 Asterion Ltd Growth factor
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
GB0717985D0 (en) * 2007-07-20 2007-10-24 Asterion Ltd Growth hormone fusion proteins
GB0719818D0 (en) 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
WO2009077731A2 (en) * 2007-12-19 2009-06-25 Asterion Limited Prolactin fusion proteins
WO2011085070A2 (en) * 2010-01-06 2011-07-14 Virginia Tech Intellectual Properties, Inc. Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
JP5412323B2 (ja) 2010-02-26 2014-02-12 日東電工株式会社 貼付製剤
GB201104285D0 (en) 2011-03-15 2011-04-27 Asterion Ltd Modified receptor fusion proteins
EP2606908A1 (de) 2011-12-19 2013-06-26 Ipsen Pharma S.A.S. Neuartige pharmazeutische Zusammensetzung für ein lang wirkendes Wachstumshormonfusionsprotein (LAGH)
DK2809400T3 (en) 2012-02-03 2019-03-04 Antisense Therapeutics Ltd COMBINATION THERAPY INCLUDING A GROWTH HORMON VARIANT AND AN OIGONUCLEOTIDE BINDING TO THE GROWTH HORMON RECEPTOR
CN105229035A (zh) * 2013-03-11 2016-01-06 诺和诺德保健股份有限公司 生长激素化合物
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
EP3355931B1 (de) 2015-10-01 2024-06-26 Novo Nordisk A/S Proteinkonjugate
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
EP3820497A4 (de) * 2018-07-11 2022-03-23 Ohio University Inhibitoren der wachstumshormonwirkung auf peptid-basis und verfahren zu deren verwendung

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
NZ260103A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin with alterations in the alpha-helix-1 region
HUT69963A (en) * 1990-12-13 1995-09-28 Upjohn Co Non-naturally-occuring fusion proteins and process for preparing them
JP3417558B2 (ja) * 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド 配位子作用薬および拮抗薬の選択
IT1251895B (it) * 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
US5686268A (en) * 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
DK0851925T3 (da) * 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
ATE216723T1 (de) * 1996-02-13 2002-05-15 Japan Chem Res Hormones de croissance humaines mutantes et leur utilisation
JP2000516472A (ja) 1996-08-16 2000-12-12 メディカル リサーチ カウンシル 組織特異的遺伝子発現を与える自己複製型エピソーム性発現ベクター
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1290170A2 (de) * 2000-06-16 2003-03-12 Asterion Limited Bindungsreagenzien: chimäre ligand/rezeptorproteine
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins

Also Published As

Publication number Publication date
PL210714B1 (pl) 2012-02-29
CN101638437A (zh) 2010-02-03
GB2389115B (en) 2005-03-16
IL200659A0 (en) 2010-05-17
HUP0402496A2 (hu) 2005-03-29
JP2010043100A (ja) 2010-02-25
SG160205A1 (en) 2010-04-29
HUP0402496A3 (en) 2012-03-28
GB2384001A (en) 2003-07-16
EP1456385A2 (de) 2004-09-15
KR20040083470A (ko) 2004-10-02
AU2002366325B2 (en) 2008-04-24
ZA200600149B (en) 2006-10-25
RU2004117777A (ru) 2005-05-10
WO2003070765A2 (en) 2003-08-28
RU2346047C2 (ru) 2009-02-10
GB2384001B (en) 2004-02-04
KR20070108254A (ko) 2007-11-08
NZ533550A (en) 2006-02-24
ES2378424T3 (es) 2012-04-12
CN100558899C (zh) 2009-11-11
EP1456385B1 (de) 2012-01-18
US20050123558A1 (en) 2005-06-09
US7524649B2 (en) 2009-04-28
AU2002366325A1 (en) 2003-09-09
ZA200404488B (en) 2006-03-29
PL371313A1 (en) 2005-06-13
CN1604965A (zh) 2005-04-06
HK1070669A1 (en) 2005-06-24
US20090239801A1 (en) 2009-09-24
CA2468439A1 (en) 2003-08-28
GB0130052D0 (en) 2002-02-06
KR100879553B1 (ko) 2009-01-22
GB0320479D0 (en) 2003-10-01
MXPA04005675A (es) 2005-04-19
EP2365085A1 (de) 2011-09-14
IL162433A (en) 2011-09-27
KR100848802B1 (ko) 2008-07-28
IL162433A0 (en) 2005-11-20
WO2003070765A3 (en) 2003-11-27
JP5248734B2 (ja) 2013-07-31
GB2389115A (en) 2003-12-03
KR20060106862A (ko) 2006-10-12
JP2005525106A (ja) 2005-08-25
RU2008118104A (ru) 2009-11-20

Similar Documents

Publication Publication Date Title
ATE541935T1 (de) Wachstumshormon fusionprotein
DK1305411T3 (da) Fremgangsmåde til frembringelse af funktionelle proteindomæner
DE60040225D1 (en) Erythropoietin immunglobulin fusionsproteine
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
DE60333306D1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
PL336306A1 (en) Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
DE60325892D1 (de) Stellungs- und verwendungsverfahren
ATE353921T1 (de) Chimäre polypeptide, verfahren zur herstellung und verwendung dafür
CY1106966T1 (el) Αντισωμα αντι-αpο-2
PL1833847T3 (pl) Polipeptydy fuzyjne IGF-1 oraz ich zastosowanie terapeutyczne
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
EP1539809A4 (de) Hcv-fusionsproteine mit modifizierten ns3-domänen
EP1523492A4 (de) Igg-fc/hiv-gp120/c3d-fusionsprotein
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
EP1385532A4 (de) Stimulation der osteogenese mit rang-ligandenfusionsproteinen
DK1171470T3 (da) Antistoffer over for placentaprotein 13
DE10082298D2 (de) Chimäre Proteine
DE60028365D1 (de) Chimäre nukleinsäuren und polypeptide aus lyssavirus
NO20021244L (no) Subenhet-optimaliserte fusjonsproteiner
WO2004005335A3 (en) Multimerised growth hormone fusion proteins
ATE404576T1 (de) Neuartiges polypeptid und dessen kodierende nukleinsäuren
ATE480262T1 (de) Fusionsproteine